ELISA: Principles, Formats, and Forensic Applications

All ELISA formats share the same five-stage procedure, regardless of the specific antibody arrangement. Understanding each stage explains why the assay achieves both high sensitivity and low background signal.

• Coating: the capture molecule (antibody or antigen) is incubated in the wells of a polystyrene microplate and adsorbs non-covalently to the plastic surface. After coating, unbound material is removed by washing.
• Blocking: a protein solution (bovine serum albumin, skimmed milk, or casein) is added to occupy remaining binding sites on the plate. This prevents non-specific adsorption of subsequent reagents, which would raise background and reduce the signal-to-noise ratio.
• Sample and primary antibody incubation: the sample (or primary antibody) is added and incubated. Specific binding occurs. Unbound material is removed by washing. Multiple wash cycles are critical; residual unbound enzyme conjugate in subsequent steps is the main source of false-positive signal.
• Enzyme conjugate incubation: the enzyme-labelled detection reagent is added. It binds to whatever immunological partner is already in the well. Unbound conjugate is again removed by washing.
• Substrate addition and reading: the substrate solution is added. The enzyme converts it to a coloured product over a fixed incubation period. A stop reagent (typically sulphuric acid for TMB/HRP) halts the reaction. The plate reader measures optical density at the appropriate wavelength, and the values are read against a standard curve.

The four principal formats differ in how the antibody-antigen system is arranged, which determines the format's sensitivity, specificity, and the type of target analyte it suits.

The direct format is the simplest: antigen is coated onto the plate, and a single enzyme-labelled antibody binds it directly. It is fast and avoids secondary antibody cross-reactivity but is less sensitive than indirect or sandwich formats and requires that every primary antibody be individually conjugated to the enzyme.

The indirect format adds a second step: an unlabelled primary antibody binds the coated antigen, and a labelled secondary antibody (directed against the species of the primary) provides the signal. The secondary antibody amplifies the signal because multiple secondary antibody molecules can bind each primary. Indirect ELISA is the format used in forensic and clinical serology to detect antibodies in blood samples, for example, in testing for blood group antibodies or in species-origin testing where an anti-species antibody is the primary reagent.

The sandwich format offers the highest specificity of the four. A capture antibody is coated onto the plate. Sample is added, and the target antigen binds the capture antibody. A second detection antibody, directed at a different epitope on the same antigen, is added and provides the signal. Both antibodies must bind for a positive result, which requires that the target be present in its intact form. Sandwich ELISA is the preferred format for detecting body-fluid-specific proteins such as prostate-specific antigen (PSA) in forensic semen identification.

The competitive format works differently from the others. Labelled antigen (or labelled antibody) competes with the unlabelled analyte in the sample for a fixed quantity of binding sites. When sample analyte is absent, all the labelled antigen binds and the signal is maximal. As sample analyte concentration increases, it displaces labelled antigen and signal decreases. This inverse relationship is the diagnostic feature of competitive ELISA. It is the standard format for drugs of abuse, because small drug molecules (haptens) cannot present two separate epitopes to two separate antibodies.

Body fluid identification is one of the first steps in biological evidence processing. Confirming the nature of a stain before proceeding to DNA profiling establishes its biological relevance and guides interpretive reporting. ELISA-based tests have displaced many earlier colorimetric and microscopic presumptive methods for several body fluids because they are more sensitive, more specific, and less prone to interference from substrates or environmental contaminants.

Semen identification uses antibodies against prostate-specific antigen (PSA, also called p30 in older forensic literature). PSA is produced by the prostate gland and is highly concentrated in seminal plasma. Sandwich ELISA kits for PSA reliably detect semen at dilutions corresponding to stains that fail the acid phosphatase colorimetric test or microscopic spermatozoa search. PSA is detectable in vaginal swabs many hours after intercourse and persists in dried stains for years. Importantly, PSA can be present at very low levels in female periurethral glands; the forensic interpretation must account for this, and a quantitative threshold (typically greater than 4 nanograms per millilitre in extracted stain material) is often applied.

Blood identification at the ELISA level uses antibodies against human haemoglobin or human-specific albumin. These tests distinguish human blood from the blood of other species, which is relevant when bloodstains are found on hunting equipment or wildlife crime exhibits. Saliva identification uses antibodies against salivary amylase (amylase is not exclusively salivary, so combined amylase and salivary-specific protein assays are preferred). Vaginal secretion identification and menstrual blood identification are areas of active method development; mRNA-based approaches are now displacing ELISA for some of these.

Drug screening by ELISA uses competitive format assays. Commercial immunoassay panels (ELISA or closely related enzyme immunoassay (EIA) formats) are available for virtually every class of drug encountered in forensic toxicology: opioids, cannabinoids, cocaine metabolites, amphetamines, benzodiazepines, phencyclidine, and many more. These panels are the standard first-line screen for workplace drug testing, postmortem toxicology, and driving-under-the-influence cases in jurisdictions including the US, UK, India, and across the EU.

The primary limitation of ELISA drug screening is cross-reactivity. Antibodies raised against a target drug class often bind structurally similar compounds. An opiate antibody designed to detect morphine may also react with codeine, hydromorphone, or oxycodone. An amphetamine antibody may react with pseudoephedrine. This cross-reactivity is intentional in multi-class screen design (the goal is to flag any opioid, not just one specific opioid), but it means the positive result cannot identify which specific drug is present. Cross-reactivity with non-drug dietary compounds (poppy seed consumption elevating opiate screen results, for example) also occurs and is a documented source of false positives in workplace screening.

Forensic confirmation of a positive ELISA drug screen uses liquid chromatography-tandem mass spectrometry (LC-MS/MS) or gas chromatography-mass spectrometry (GC-MS). These methods identify the specific compound and quantify it, eliminating cross-reactivity as a confounding factor. The two-step workflow, immunoassay screen followed by mass spectrometry confirmation, is the legally mandated approach in US federal workplace testing (49 CFR Part 40), in UK roadside drug testing frameworks, and in Indian postmortem toxicology laboratories operating under the guidelines of the Central Forensic Science Laboratory.

Hair and oral fluid drug testing extend the ELISA approach beyond urine. ELISA kits validated for hair extracts can detect drug use over weeks to months by analysing segments of hair corresponding to different growth periods. Oral fluid ELISA kits detect recent drug use and are used in roadside testing programmes in Australia, several European Union member states, and pilot programmes in India. The matrices differ from urine in their protein content and pH, requiring format-specific validation to maintain sensitivity and specificity.

Species identification determines whether biological material originates from a human or an animal, and if animal, which species. This is relevant in wildlife crime, meat adulteration, and cases where the origin of a bloodstain is disputed. ELISA provides a serological approach to species ID that complements DNA-based methods.

The precipitin test developed by Uhlenhuth in 1901 was the first immunological species test, using antiserum against human blood to differentiate human from animal stains. ELISA replaces the precipitin reaction with a more sensitive and quantifiable format. Anti-species antibodies (antibodies raised in one species against the serum proteins of another) are used as the primary detection reagent. A sandwich or indirect ELISA using an anti-human albumin or anti-human IgG primary antibody will react with human blood stains but not with stains from other species unless significant cross-reactivity exists between the human protein and its homologue in a closely related species.

Wildlife forensics uses ELISA panels targeting species-specific proteins to identify seized products as belonging to protected species. Ivory can be tested with antibodies against elephant-specific proteins; tiger or leopard tissue can be tested with anti-felid antibodies. The Convention on International Trade in Endangered Species (CITES) enforcement operations in range states including India, Kenya, and Thailand, and at border inspection posts in the EU and US, use ELISA panels as a rapid screening tool before DNA confirmation. The limitation is that a negative ELISA result for one species panel does not rule out all protected species; comprehensive species ID requires DNA.

Meat species identification for food fraud investigation uses similar principles. Antibodies against species-specific myosin heavy chain isoforms or serum albumin can distinguish beef from horse, pork from chicken, or sheep from goat in processed food products. ELISA panels for this application were deployed extensively across European Union member states following the 2013 horse meat scandal. The Food Safety and Standards Authority of India (FSSAI) has adopted ELISA-based panels as part of its food adulteration detection protocols. The UK's Food Standards Agency and the US FDA have analogous validated methods.

Sensitivity in an ELISA context refers to the minimum concentration of analyte that produces a signal reliably distinguishable from background (the analytical detection limit). Forensic ELISA tests for body fluid proteins typically achieve detection limits of 1 to 10 nanograms per millilitre of extract. Drug immunoassays commonly achieve limits in the range of 10 to 100 nanograms per millilitre, depending on the drug class. These limits are set to exceed the minimum concentration expected from a genuine positive sample while remaining comfortably above the assay's background noise.

Specificity describes how well the assay distinguishes the target analyte from other substances in the sample matrix. Antibody specificity is determined during development by testing panels of potentially interfering compounds. In diagnostic and forensic contexts, specificity is often reported as the percentage of true negatives correctly identified. High specificity minimises false positives; high sensitivity minimises false negatives. The two properties trade off against each other when antibody affinity or detection threshold is adjusted.

Quality control in forensic ELISA follows the same principles as ISO 17025-accredited analytical testing generally. Each run must include a negative control (blank or confirmed-negative matrix), a positive control at or near the detection limit (low positive), and a positive control at a concentration well above the threshold (high positive). The run is only accepted if controls fall within pre-defined acceptance criteria. If any control fails, the entire run is repeated. Standards used to construct the calibration curve must be prepared from independently sourced reference materials, not from the same stock as the samples being tested.

Comparison with radioimmunoassay (RIA) is relevant for laboratories transitioning older protocols. RIA achieves similar or slightly superior sensitivity to ELISA for some analytes, using radioactively labelled antigens or antibodies. Both methods use competitive or direct formats. RIA remains in use in some specialised toxicology and endocrinology settings but has been replaced by ELISA in the majority of forensic laboratories because enzyme substrates are non-radioactive, stable at room temperature, and do not require radiation safety infrastructure. The lateral-flow immunoassay (the technology used in pregnancy tests and rapid drug screening devices) is a further simplification: it uses the same antibody principles as ELISA but replaces enzyme-substrate colour development with colloidal gold or coloured latex particles visible to the naked eye. Lateral-flow tests sacrifice quantitative precision for speed and portability, and are used as field screening tools rather than laboratory confirmatory tests.